Guias de manejo melanoma no operable 2026

A clinical practice guideline has been published that provides recommendations on the use of systemic therapy in patients with unresectable, metastatic cutaneous melanomas. These guidelines were published by Cancer Care Ontario.

The evidence-based recommendations apply to adults with unresectable nodal or distant metastatic cutaneous melanoma, defined as American Joint Committee on Cancer (AJCC) 8th edition stage IIIC/D or stage IV, who are candidates for systemic therapy. Intended users of the guideline include medical oncologists, dermatologists, and other clinicians involved in melanoma care. The recommendations reflect a decade-long therapeutic shift driven by immune checkpoint inhibitors — including anti-programmed cell death protein 1 (anti-PD-1) inhibitors, anti-cytotoxic T-lymphocyte-associated protein 4 (anti-CTLA-4) inhibitors, and anti-lymphocyte-activation gene 3 (anti-LAG-3) agents — and BRAF/MEK-targeted therapies.

First-Line Therapy: BRAF Wild-Type Disease

For patients with BRAF wild-type melanoma, recommended first-line options include nivolumab plus ipilimumab, nivolumab plus relatlimab, nivolumab monotherapy, and pembrolizumab monotherapy.

Nivolumab 1 mg/kg plus ipilimumab 3 mg/kg is to be administered intravenously once every 3 weeks for 4 total doses, followed by nivolumab 3 mg/kg every 4 weeks until progression, toxicity, or the need for other treatment considerations. Nivolumab 480 mg plus relatlimab 160 mg should be administered intravenously every 4 weeks until progression. Nivolumab monotherapy is to be administered intravenously in a dose of 3 mg/kg every 2 weeks or 6 mg/kg every 4 weeks, with either dose continued until progression, toxicity, or other considerations. Similarly, pembrolizumab is to be administered intravenously in a dose of 2 mg/kg every 3 weeks or 6 mg/kg every 4 weeks for a maximum of 2 years, with the potential for retreatment for 1 year.

Due to the evolving environment surrounding systematic therapy for unresectable, metastatic melanoma, indications and approvals are changing rapidly.

Evidence is anchored in a 2018 Cochrane review and multiple randomized controlled trials. Anti-PD-1 therapy (nivolumab or pembrolizumab) significantly improved overall survival (OS) and progression-free survival (PFS) compared with ipilimumab, with lower rates of grade 3-4 toxicity. Better PFS but higher rates of grade 3-4 treatment-related adverse events occurred with nivolumab combination therapy vs nivolumab monotherapy. Nivolumab plus relatlimab demonstrated improved PFS compared with nivolumab alone, with higher toxicity rates than nivolumab alone but lower than with nivolumab plus ipilimumab. While chemotherapy remains an option, immunotherapy is preferred due to superior survival outcomes.

First-Line Therapy: BRAF-Mutated Disease

For patients with BRAF-mutated melanoma, both immunotherapy and targeted therapy are recommended. In addition to the recommended treatment options for BRAF-wild type melanoma, patients with BRAF-mutated melanoma may also receive BRAF/MEK inhibitor combinations of dabrafenib plus trametinib, encorafenib plus binimetinib, or vemurafenib plus cobimetinib. However, immunotherapy is preferred as first-line treatment based on sequencing data.

Dosing for nivolumab plus relatlimab and nivolumab monotherapy are the same for patients with BRAF-mutated disease as patients with BRAF-wild type disease. Nivolumab plus ipilimumab is to be administered intravenously every 3 weeks for up to 4 doses, followed by nivolumab 6 mg/kg every 4 weeks until progression, toxicity, or other considerations. Pembrolizumab monotherapy is available intravenously for up to 2 years with a 1-year potential retreatment period in a dose of 2 mg/kg every 3 weeks, 4 mg/kg every 6 weeks, or 6 mg/kg every 4 weeks. Dabrafenib 150 mg should be taken twice daily and trametinib 2 mg should be taken once daily, both orally. Similarly, encorafenib 450 mg should be taken once daily while binimetinib 45 mg should be taken twice daily, both orally. Vemurafenib 960 mg should be taken twice daily with cobimetinib 60 mg once daily for 21 days with a 7-day rest period in each 28-day cycle.

Combination BRAF/MEK inhibitors vs BRAF monotherapy consistently demonstrated improved outcomes with a reduced mortality risk without increased toxicity in pooled analyses. Improved PFS and OS were observed with encorafenib plus binimetinib vs vemurafenib. Other trials similarly supported dabrafenib plus trametinib.

Triplet regimens (BRAF/MEK plus anti-PD-1/PD-L1) yielded mixed results. Some analyses demonstrated PFS improvements but triple-therapy regimens did not consistently improve OS and were associated with higher grade 3-4 toxicity than double-therapy regimens.

Sequencing trials provide key guidance. Superior 2-year OS and PFS were observed when patients received nivolumab plus ipilimumab first, followed by targeted therapy at progression. Sustained superiority of immunotherapy-first strategies was confirmed at 5 years. Initial immunotherapy, with or without short targeted therapy, was preferred over targeted therapy-first approaches. Continuous BRAF/MEK dosing was superior to intermittent dosing.

PD-1-Refractory Disease

For patients with BRAF wild-type melanoma who are refractory to PD-1 monotherapy (including both primary and acquired resistance), recommended options include nivolumab plus ipilimumab or pembrolizumab plus ipilimumab. Nivolumab plus ipilimumab improved PFS compared with ipilimumab alone.

For PD-1-refractory BRAF-mutant melanoma, options include combination immunotherapy with nivolumab plus ipilimumab, nivolumab plus relatlimab, or pembrolizumab plus ipilimumab, as well as BRAF/MEK inhibitors. Subgroup analyses showed PFS benefits for pembrolizumab in certain previously treated BRAF-mutant populations.

Dosing schedules for all regimens are consistent among patients who are and are not refractory to PD-1 monotherapy.

Molecular and Clinical Subtypes

For NRAS-mutant melanoma, binimetinib may be considered with or without immunotherapy. Binimetinib improved PFS compared with dacarbazine, although responses were modest.

For KIT-mutant melanoma, evidence is limited to single-arm studies. Due to low-quality evidence and absence of randomized controlled trials, no specific recommendation is made beyond following general systemic therapy guidance.

For brain metastases, nivolumab plus ipilimumab is recommended. In trials evaluating patients with asymptomatic brain metastases, greater rates of intracranial response were observed with combination therapy vs nivolumab alone. Combination immunotherapy was also favored over chemotherapy-based approaches based on 7-year OS data. Further, BRAF/MEK inhibitors demonstrated promising intracranial response rates in BRAF V600-mutant brain metastases, although responses were less durable than in extracranial disease. Radiation therapy, particularly stereotactic approaches, remains an important component of multidisciplinary care.

Implementation and Evidence Limitations

For all patients, clinical trial participation is encouraged when standard options fail or are not acceptable.

The guideline emphasizes shared decision-making, balancing OS/PFS benefits against toxicity, patient comorbidities, and preferences. Toxicity profiles vary significantly, particularly with combination immunotherapy.

Key limitations include the lack of direct head-to-head randomized controlled trial comparisons between immunotherapy and targeted therapy, limited predictive biomarkers beyond BRAF mutation status, and reliance on subgroup analyses for brain metastases and refractory populations. Heterogeneity across trials precluded meta-analysis. Cost-effectiveness was outside the scope of these recommendations.

Future Directions

Further biomarker-driven research is needed to personalize therapy, optimize sequencing, and refine treatment duration strategies. Ongoing trials in NRAS-mutant disease and novel combinations may further evolve the therapeutic landscape.

Overall, the guideline reflects a paradigm in which immunotherapy, particularly in blocking combination immune checkpoints, provides durable survival benefit and is generally favored as first-line therapy, with targeted therapy integrated strategically based on mutation status, disease progression, and clinical circumstances.

Guideline authors concluded, “Due to the evolving environment surrounding systematic therapy for unresectable, metastatic melanoma, indications and approvals are changing rapidly.”

References:

Petrella T, Kellett S, Knight G, et al; Melanoma Disease Site Group. Systemic treatments for unresectable and metastatic cutaneous melanoma. Cancer Care Ontario. Published January 5, 2026. Accessed February 17, 2026. https://www.cancercareontario.ca/en/guidelines-advice/types-of-cancer/79966

Lisa Kuhns, PhD

Lisa Kuhns, PhD is an experienced medical writer specializing in news-focused content for healthcare professionals. With over 15 years in the life sciences and 5 years of freelance experience, she brings a keen editorial eye and scientific rigor to the development of timely, clinically relevant news articles and summaries. Lisa also has extensive experience supporting accredited continuing medical education (CME), including the development of needs assessments and expert-driven slide decks across multiple therapeutic areas. Her work supports evidence-based clinical decision-making and bridges science and medicine to keep clinicians informed and engaged. Website: www.lgkmedicalwriting.com LinkedIn: https://www.linkedin.com/in/lisakuhns/